FindTrial
Sign In

A phase II study of gefitinib in PS3 (4) advanced adenocarcinoma of the lung

A phase II study of gefitinib in PS3 (4) advanced adenocarcinoma of the lung - Poor PS:Gefitinib

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-C000000187
Enrollment
30
Registered
2005-09-12
Start date
2003-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PS 3 patients (or PS 4 patients because of bone or brain metastasis) with advanced adenocarcinoma of the lung.

Interventions

The treatment schedule included gefitinib at 250mg/day, administered once daily.

Sponsors

Department of Medical Oncology, Kinki University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with histologic or cytologic confirmation of adenocarcinoma of the lung regardless of previous chemotherapy were eligible. The eligibility criteria were as follows; (1) measurable lesions; (2) age ≥ 20, (3) Eastern Cooperative Oncology Group (ECOG) performance status (PS) 3 (4; because of bone or brain metastasis) (4) adequate organ function

Exclusion criteria

Exclusion criteria: The exclusion criteria consisted of pulmonary fibrosis or interstitial pneumonitis with apparent abnormalities on chest X-ray, acute inflammation, symptomatic brain metastases, active concurrent malignancies, severe drug allergies, severe heart disease, uncontrollable diabetes mellitus, severe infection.

Design outcomes

Primary

MeasureTime frame
Overall response rate—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026